| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
556 |
375 |
$77K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
530 |
391 |
$50K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
325 |
323 |
$44K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
312 |
234 |
$13K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
126 |
124 |
$10K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
246 |
246 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
92 |
72 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
12 |
12 |
$261.24 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
15 |
15 |
$207.96 |
| 81025 |
|
16 |
12 |
$189.04 |